Therefore, we believe that the high expression of IGF2BPs may be one of the factors leading to the occurrence and development of LUAD in patients, and further study of the mechanism of IGF2BP1 in malignant tumors may be expected to provide a new method for tumor-targeted therapy. This evidence concerns the gene IGF2BP1 and neoplasm.